- Home
- CNSP
as 12-18-2024 11:45am EST
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | HOUSTON |
| Market Cap: | 5.4M | IPO Year: | 2019 |
| Target Price: | $0.50 | AVG Volume (30 days): | 6.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.99 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.10 - $71.00 | Next Earning Date: | 11-15-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest CNS Pharmaceuticals Inc. News
CNSP Breaking Stock News: Dive into CNSP Ticker-Specific Updates for Smart Investing
ACCESSWIRE
13 days ago
CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024
ACCESSWIRE
23 days ago
CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy
ACCESSWIRE
a month ago
CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)
ACCESSWIRE
a month ago
CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results
ACCESSWIRE
a month ago
CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment
MT Newswires
2 months ago
CNS Pharmaceuticals Receives More Time to Regain Compliance With Nasdaq Listing Requirement
ACCESSWIRE
2 months ago
CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
ACCESSWIRE
2 months ago
CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Compare CNSP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CNSP CNS Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.